Related Experiment Video
Updated: Feb 20, 2026
08:11
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
23.7K
AG488 as a therapy against gliomas.
Jadith Ziegler1,2, Anja Bastian3, Megan Lerner4
1Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Oncotarget
|October 27, 2017
Summary
The small molecule AG488 shows promise as a novel therapy for high-grade gliomas. It effectively reduced glioblastoma cell viability and tumor growth in preclinical models with anti-angiogenic and anti-microtubule effects.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pharmacology
Background:
- High-grade gliomas, including glioblastomas (GBM), have a poor prognosis and limited treatment options.
- Novel therapeutic strategies are urgently needed to improve outcomes for GBM patients.
Purpose of the Study:
- To investigate the efficacy of the small molecule AG488 as a potential therapy for glioblastoma.
- To evaluate AG488's anti-angiogenic and anti-microtubule inhibitory effects against GBM.
Main Methods:
- In vitro studies using G55 glioma and HMEC-1 cells, as well as normal astrocytes.
- In vivo investigations utilizing a human G55 glioma xenograft model in nude mice.
- Assessment of cell viability, tumor volume, animal survival, tumor perfusion, and microvessel density (MVD).
Main Results:
- AG488 significantly reduced G55 and HMEC-1 cell viability more than temozolomide (TMZ) in vitro.
- In vivo, AG488 decreased tumor volumes, prolonged survival, increased tumor perfusion, and reduced MVD.
- AG488 demonstrated comparable efficacy to TMZ or anti-VEGF therapies but was more effective in reducing tumor vascularity.
Conclusions:
- AG488 exhibits potent anti-cancer activity against high-grade gliomas through dual mechanisms.
- AG488 represents a potential novel therapeutic agent for glioblastoma treatment.
- Further clinical investigation of AG488 for high-grade gliomas is warranted.
